Publication: Vitamin E neuroprotection for cisplatin neuropathy
| Reference | |
|---|---|
| Title | Vitamin E neuroprotection for cisplatin neuropathy |
| Topic | Vitamin E |
| Author | Pace, A, Giannarelli, D, Galie, E, Savarese, A, Carpano, S, Della Giulia, M, Pozzi, A, Silvani, A, Gaviani, P, Scaioli, V, Jandolo, B, Bove, L, Cognetti, F |
| Year | 2010 |
| Journal | Neurology |
| DOI | https://doi.org/10.1212/WNL.0b013e3181d5279e |
Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.
| The clinical use of platinum-based antineoplastic agents is limited by severe peripheral neurotoxicity reported in up to 90% of patients receiving a cumulative dose higher than 300 mg/m². Recent studies support that cisplatin-induced neuropathy is related to degeneration of large dorsal root ganglion cell bodies with the loss of large myelinated fibers. Evidence suggests that side effects induced by cisplatin treatment are, at least in part, the result of the formation of free radicals. Several studies have reported interesting results of vitamin E supplementation against cisplatin peripheral neurotoxicity. In animals, supplementation with antioxidants (vitamin E and C, selenium) protects against renal toxicity and ototoxicity induced by cisplatin; moreover, human studies indicate that cisplatin treatment induces a decrease in plasma antioxidant levels due to oxidative stress. It has been noticed that clinical and neuropathologic features observed in cisplatin-induced neuropathy are similar to those observed in vitamin E deficiency neuropathy. In a previous study, we reported a significant neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. A recent Cochrane review analyzed neuroprotective strategies in cisplatin neuropathy including vitamin E supplementation, reporting the encouraging but inconclusive results of several studies. The review concluded that there is a lack of randomized controlled trials using objective measures of neuropathy and including adequate numbers of patients. The aim of the present phase III, randomized, placebo-controlled study is to confirm the neuroprotective effect of vitamin E supplementation in patients treated with cisplatin. |
This publication is referenced in the following studies: